This trial will study the safety of using cord blood stem cells in patients with conditions that affect the blood or immune system.
1 Primary · 1 Secondary · Reporting Duration: within 48 hours of infusion
1 Treatment Group
1 of 1
9999 Total Participants · 1 Treatment Group
Primary Treatment: unlicensed CBU · No Placebo Group · Phase 2
Who is running the clinical trial?
Age Any Age · All Participants · 3 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Who else is applying?
What state do they live in?
What portion of applicants met pre-screening criteria?
|Did not meet criteria||100.0%|
Frequently Asked Questions
How many participants can join this research program?
"Correct. Data found on clinicaltrials.gov indicates that this research project is actively recruiting participants, which commenced being posted on February 1st 2012 and was recently modified on April 19th 2022. A total of 9999 patients are being sought from 67 distinct medical facilities." - Anonymous Online Contributor
Is this research endeavor currently accessible to participants?
"Current information posted to clinicaltrials.gov shows that this research project is recruiting participants. Its first post was on February 1st 2012 and the details were most recently updated April 19th 2022." - Anonymous Online Contributor
What risks could potentially accompany the unauthorized use of CBU?
"Our team at Power has assigned unlicensed CBU a score of 2, as the drug is currently being tested in Phase 2 trials and thus there are some safety data but no efficacy evidence." - Anonymous Online Contributor
Are there many venues conducting this research endeavor in North America?
"Participating in this medical trial is possible for those near many different locations, such as the Florida Hospital, Florida Center for Cellular Therapy based in Orlando FL, St. Louis University Hospital located in Saint Louis MO, and Northwestern Memorial Hospital in Chicago IL." - Anonymous Online Contributor